CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

Puma Biotechnology Q3 2026 net income falls 32% to $6 million

By Public Technologies
  • Puma Biotechnology’s third-quarter 2026 net income fell 32% year over year to $6 million.
  • Total revenue rose to $55.1 million, while research and development expenses climbed 15% to $18.3 million.
  • Quarterly cash provided by operating activities jumped 51% to $14.6 million.
  • During the quarter, Puma initiated ALISCA-Lung2, a Phase II trial evaluating alisertib with paclitaxel in advanced small cell lung cancer.
  • Full-year 2026 net income guidance increased to $20 million–$22 million from $17 million–$20 million.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Puma Biotechnology Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261105266638) on November 05, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk